Viatris Innovation Gmbh
Clinical trials sponsored by Viatris Innovation Gmbh, explained in plain language.
-
New lupus pill shows promise in reducing disease activity
Disease control CompletedThis study tested a daily pill called cenerimod in 427 adults with moderate to severe systemic lupus erythematosus (SLE). The goal was to see if it could safely reduce lupus disease activity over 6 months compared to a placebo. Participants continued their usual lupus medications…
Phase: PHASE2 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New lupus drug shows promise in early trial
Disease control CompletedThis study tested a new drug called cenerimod in 105 people with active lupus. The goal was to see if it safely lowers certain immune cells (lymphocytes) that play a role in lupus. Participants took the drug or a placebo for up to 12 weeks while continuing their usual lupus medic…
Phase: PHASE1, PHASE2 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
Liver function and drug processing: a safety study
Knowledge-focused CompletedThis study looked at how the drug cenerimod is handled by people with mild or moderate liver problems compared to healthy people. 24 adults received a single dose to measure drug levels and safety. The goal was to understand if liver impairment changes how the drug works, which h…
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 26, 2026 04:13 UTC
-
Healthy men help track Drug's journey through the body
Knowledge-focused CompletedThis study looked at how the drug cenerimod is broken down and removed from the body. Six healthy men aged 45 to 65 took a single dose with a radioactive marker. Researchers measured the drug in urine, stool, and breath to understand its elimination.
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 26, 2026 04:11 UTC
-
Kidney disease drug study: no treatment, just science
Knowledge-focused CompletedThis study looked at how the body processes a single dose of the drug cenerimod in people with severe kidney impairment compared to healthy volunteers. A total of 16 adults took part. The goal was to measure drug levels and safety, not to treat any disease.
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 26, 2026 03:55 UTC
-
Healthy volunteer study probes Cenerimod's heart and pill interactions
Knowledge-focused CompletedThis study looked at how the drug cenerimod affects the heart's electrical activity (QT interval) in 97 healthy adults. It also tested whether cenerimod changes how birth control pills work in the body and how charcoal influences cenerimod levels. Participants received either pla…
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 26, 2026 03:55 UTC
-
Healthy volunteers help scientists understand new drug selatogrel
Knowledge-focused CompletedThis study tested a single 16 mg dose of selatogrel in 32 healthy adults (16 Japanese, 16 Caucasian) to see how the body absorbs and breaks down the drug, and whether it causes side effects. Participants stayed in a clinic for 3-4 days and had follow-up visits. The study is compl…
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC
-
Healthy volunteers help test new Drug's safety
Knowledge-focused CompletedThis study is for research only and does not treat any disease. It tests how safe a single dose of cenerimod is and how the body processes it in 20 healthy adults (10 Japanese, 10 Caucasian). Participants stay in the clinic for 4 days and have follow-up visits over about 75 days.
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC
-
Healthy men help scientists track drug absorption in tiny radioactivity study
Knowledge-focused CompletedThis study looked at how much of the drug cenerimod enters the bloodstream after taking a pill. Six healthy men took one tablet and later received a tiny radioactive tracer through a vein to measure the drug's absorption. The study was done for research only and did not treat any…
Phase: PHASE1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC